GlassScriptPhysician profile
Jude A Pierre
NPI 1669474219
$999.99
in general payments reported to CMS, 2019-2025
18 companies · $90.76 in 2025
The $90.76 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $26.83 · 2021: $231 · 2022: $102 · 2023: $272 · 2024: $145 · 2025: $90.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $172.40 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $128.97 | 2021-2025 | Cresemba |
| Pfizer INC. | $105.20 | 2022-2025 | |
| Horizon Therapeutics Plc | $101.09 | 2021-2022 | |
| Smith+Nephew, INC. | $96.49 | 2019-2023 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $65.09 | 2022-2025 | Breztri |
| Integra Lifesciences Corporation | $59.07 | 2021-2022 | |
| Amgen INC. | $42.96 | 2019-2024 | Otezla, Repatha |
| Averitas Pharma INC. | $39.30 | 2024 | Qutenza |
| Novartis Pharmaceuticals Corporation | $33.51 | 2023 | |
| Novo Nordisk INC | $27.32 | 2019-2023 | Wegovy |
| Dexcom, INC. | $22.59 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $22.24 | 2024 | Mounjaro |
| Amarin Pharma, INC. | $19.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.12 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Treace Medical Concepts, INC. | $17.05 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jude Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.